GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » MusclePharm Corp (OTCPK:MSLPQ) » Definitions » Interest Coverage

MusclePharm (MusclePharm) Interest Coverage : 0 (At Loss) (As of Mar. 2022)


View and export this data going back to 2008. Start your Free Trial

What is MusclePharm Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. MusclePharm's Operating Income for the three months ended in Mar. 2022 was $-2.48 Mil. MusclePharm's Interest Expense for the three months ended in Mar. 2022 was $-0.64 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for MusclePharm's Interest Coverage or its related term are showing as below:


MSLPQ's Interest Coverage is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 8.4
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


MusclePharm Interest Coverage Historical Data

The historical data trend for MusclePharm's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MusclePharm Interest Coverage Chart

MusclePharm Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.63 -

MusclePharm Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 - - - -

Competitive Comparison of MusclePharm's Interest Coverage

For the Packaged Foods subindustry, MusclePharm's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MusclePharm's Interest Coverage Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, MusclePharm's Interest Coverage distribution charts can be found below:

* The bar in red indicates where MusclePharm's Interest Coverage falls into.



MusclePharm Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MusclePharm's Interest Coverage for the fiscal year that ended in Dec. 2021 is calculated as

Here, for the fiscal year that ended in Dec. 2021, MusclePharm's Interest Expense was $-2.67 Mil. Its Operating Income was $-8.91 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

MusclePharm did not have earnings to cover the interest expense.

MusclePharm's Interest Coverage for the quarter that ended in Mar. 2022 is calculated as

Here, for the three months ended in Mar. 2022, MusclePharm's Interest Expense was $-0.64 Mil. Its Operating Income was $-2.48 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

MusclePharm did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


MusclePharm  (OTCPK:MSLPQ) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


MusclePharm Interest Coverage Related Terms

Thank you for viewing the detailed overview of MusclePharm's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


MusclePharm (MusclePharm) Business Description

Traded in Other Exchanges
N/A
Address
6728 W. Sunset Road, Suite 130, Las Vegas, NV, USA, 89118
MusclePharm Corporation is a performance lifestyle company. It develops, manufactures, markets and distributes branded nutritional supplements. It offers various types of powders, capsules, tablets and gels. Geographically, the firm has its business presence across the region of US and in the international market of which the US accounts for the majority of revenue. MusclePharm's Hybrid series products include Assault, Combat Protein Powder, BCAA 3:1:2, CLA Core, Fish Oil, Combat Crunch Protein Bars, glutamine, carnitine, Combat Crunch, Protein Crisp, Organic Protein, and Protein Cookie. The group sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, and others.
Executives
Eric Chin officer: Chief Accounting Officer 1668 S. GARFIELD AVE., 2ND FLOOR, ALHAMBRA CA 91801
Paul W Karr director BRISTOL MEYERS SQUIBB CO, 345 PARK AVENUE, NEW YORK NY 10154
Sabina Rizvi officer: President & CFO 6728 W. SUNSET ROAD, SUITE 130, LAS VEGAS NV 89118
Michael David Heller director 4500 PARK GRANADA, SUITE 202, CALABASAS CA 91302
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Donald Feagan 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Amerop Holdings, Inc. 10 percent owner 1800 BROADWAY, SUITE 100, BOULDER CO 80302
White Winston Select Asset Fund Series Fund Mp-18, Llc 10 percent owner C/O WHITE WINSTON SELECT ASSET FUNDS, LLC, 265 FRANKLIN ST., SUITE 1702, BOSTON MA 02110
Robert P Mahoney 10 percent owner 4 DANIELS FARM ROAD, #305, TRUMBULL CT 06611
White Winston Select Asset Funds, Llc 10 percent owner 265 FRANKLIN STREET, SUITE 1702, BOSTON MA 02110
Todd M. Enright 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Mark Blundell 10 percent owner 8 MACDONALD AVE, ARMOUK NY 10504
John J Desmond director 10 GLEN HEAD ROAD, GLEN HEAD NY 11545
Wynnefield Small Cap Value Offshore Fund Ltd 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Capital Inc 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123